UBS Initiates Coverage On Allogene Therapeutics with Buy Rating, Announces Price Target of $8

Benzinga · 4d ago
UBS analyst Michael Yee initiates coverage on Allogene Therapeutics (NASDAQ:ALLO) with a Buy rating and announces Price Target of $8.